Rhythm Biosciences Limited · ASX:RHY
Rhythm Biosciences — Shareholder Meeting (November 2025)
15 slides from Rhythm Biosciences's shareholder meeting presentation, Nov 5, 2025
Slide 1: Post-AGM Presentation
Post-AGM Presentation 5TH NOVEMBER 2025
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Rhythm Biosciences Limited (Rhythm) and is provided for general information purposes only. No party other than Rhythm has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or undert
Slide 3: About Rhythm Biosciences
About Rhythm Biosciences We are committed to Early detection of cancer gives individuals the best possible opportunity for favorable treatment outcomes. saving lives through the evaluation of cancer risk Addressing large under-served global markets worth >USD$50bn and heavily supported by public and
Slide 4: Rhythm Bioscience: An attractive investment opportunity
Rhythm Bioscience: An attractive investment opportunity Overview Growth Reasons to Invest Rhythm’s mission is to 1. Multi-product portfolio. detect cancer earlier and Rhythm is solving an reduce the burden of important clinical and 2. Addressing a significant TAM. cancer. We are developing economic
Slide 5: When diagnosed early, cancer can be successfully treated
When diagnosed early, cancer can be successfully treated Disease stage for colorectal cancer diagnosis is the key predictor of survival Diagnoses at Stage I or II only represent less than half of all CRCs diagnosed in: Missed detection of early-stage CRC results in poor survival rates Stage I Stage
Slide 6: Detecting cancer earlier and maintaining wellness
Detecting cancer earlier and maintaining wellness The power of the combination of the Rhythm capabilities and portfolio Y N E U R Risk Assessment Disease Screening O J MONITORING AND Determination Minimally-invasive detection MINIMAL RESIDUAL T RISK ASSESSMENT DISEASE DETECTION of risk profile. of d
Slide 7: About ColoSTAT®
About ColoSTAT® ColoSTAT® has been developed as an alternative blood-based solution for use in the detection of colorectal cancer A high quality, affordable blood- A subset of the higher risk population decline the use of stool-based tests based alternative for colorectal cancer Initial intended use
Slide 8: ColoSTAT® development history
ColoSTAT® development history An extensive clinical evaluation and careful design of a high-quality assay format Assay Development: Biomarker Biomarker Clinical Pivotal Approval for Verification and Discovery Evaluation Study marketing Validation Candidate protein Biomarker evaluation Clinical evalu
Slide 9: ColoSTAT® FY26 commercial strategy
ColoSTAT ® FY26 commercial strategy Speed-to-market regulatory strategy and capital efficient commercial partnering ColoSTAT® Assay Delivery Geographical Priorities Patient symptomatic Blood sample collected for bowel cancer consults GP at phlebotomy service Channel Strategy • Health Care Profession
Slide 10: About Genetype
About Genetype A cancer risk assessment platform designed for sporadic cancer risk A unique, integrated, Scope includes 6 cancers with validation data on 100,000s of individuals personalized cancer risk assessment platform leveraging clinical and Personalised using an individual’s clinical history a
Slide 11: Genetype FY26 commercial strategy
Genetype FY26 commercial strategy Genetype FY26 Test Volumes Oncology Channel Portfolio Strategy Focus • Health Care Volume from Enterprise Accounts • Breast* Professionals – B2B • Prostate • Strategic • Colorectal* partners/ • Ovarian Enterprise accounts - • Melanoma B2B2B Volume from Clinics • Pan
Slide 12: Product launches and upgrades
Product launches and upgrades A diversified mix of development stages and underlying technologies will drive value 2nd Gen CRC ColoSTAT® Lung cancer geneTypeTM Symptomatic geneTypeTM New Product Release Q1 Q2 Q3 Q4 2028 Ordering portal geneTypeTM update geneTypeTM update geneTypeTM update Implementa
Slide 13: Our combined platforms supports a highly comprehensive product pipeline
Our combined platforms supports a highly comprehensive product pipeline COLORECTAL PANCREATIC MELANOMA JO TIENT URNEY PROSTATE CERCIVAL OVARIAN A GASTRIC P > BREAST > LUNG MONITORING AND RISK MINIMAL RESIDUAL ASSESSMENT DISEASE DETECTION Surveillance PHARMA- COGENOMICS Risk Assessment AND DRUG Drug
Slide 14: Upcoming value inflection points
Upcoming value inflection points PRODUCT ITEM DESCRIPTION COMPLETION DATE ColoSTAT® Final clinical validation Evaluation of final testing system Q3 CY 2025 geneTypeTM strategic geneTypeTM Establishment of key commercial partners Q3 CY 2025 partnerships geneTypeTM geneTypeTM menu expansion Expansion
Slide 15: Thank you!
Thank you! david.atkins@rhythmbio.com www.rhythmbio.com
Rhythm Biosciences — Shareholder Meeting (November 2025) on 6ix